Please use this identifier to cite or link to this item: http://www.repositorio.ufc.br/handle/riufc/34417
Title in Portuguese: Novel kidney injury biomarkers among anabolic androgenic steroids users - evidence of subclinical kidney disease
Author: Daher, Elizabeth de Francesco
Fernandes, Paulo Henrique Palacio Duarte
Meneses, Gdayllon Cavalcante
Bezerra, Gabriela Freire
Ferreira, Leonardo de Souza Lima
Viana, Glautemberg de Almeida
Martins, Alice Maria Costa
Silva Junior, Geraldo Bezerra da
Keywords: Anabolizantes
Anabolic Agents
Exercício
Exercise
Kidney Diseases
Nefropatias
Issue Date: Mar-2018
Publisher: Asian Journal of Sports Medicine
Citation: DAHER, E. de F. et al. Novel kidney injury biomarkers among anabolic androgenic steroids users-evidence of subclinical kidney disease. Asian J Sports Med., v. 9, n. 1, e65540, mar. 2018.
Abstract: Background: Kidney injury associated with the use of anabolic androgenic steroids (AAS) has been described. The aim of the study was to investigate new kidney injury biomarkers among bodybuilders using anabolic androgenic steroids (AAS). Methods: A cross-sectional study was conducted with a group of AAS users (n = 28) and a group of non-users (n = 29). Blood and urine samples were collected for analysis, including kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), creatinine and cystatin. Results: Laboratory tests evidenced a higher creatinine level in AAS users (1.04 0.17 mg/dL) in comparison to non-users (0.88 0.14 mg/dL), P < 0.001. Median levels of MCP-1 pg/mg-creatinine were higher in AAS users (50.66 pg/mg-creatinine, range 31.99 - 255.25 pg/mg-creatinine vs. 33.26 pg/mg-creatinine, range 22.82 - 102.98 pg/mg-creatinine, P = 0.039). KIM-1 levels were not significantly different between the two groups (0.47 0.34 ng/mg-creatinine vs. 0.69 0.47 ng/mg-creatinine, P = 0.065). Cystatin C levels showed a tendency to be higher in AAS users (0.64 0.46 mg/L vs. 0.43 0.36 mg/L, P = 0.059). Conclusions: There is subclinical kidney injury among AAS users, evidenced by MCP-1 increase. Continuous renal function monitoring and early detection of kidney injury is very important for AAS users, and more important is patient counseling to avoid these substances use, unless otherwise prescribed for treatment of some medical condition.
URI: http://www.repositorio.ufc.br/handle/riufc/34417
metadata.dc.type: Artigo
ISSN: 2008-000X
2008-7209 (Online)
Appears in Collections:PPGF - Artigos publicados em revistas científica

Files in This Item:
File Description SizeFormat 
2018_art_efdaher.pdf280,12 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.